SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Up 6.2% – Should You Buy?

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) rose 6.2% on Thursday. The stock traded as high as $7.93 and last traded at $7.93. 390,658 shares changed hands during mid-day trading, an increase of 12% from the average session volume of 348,253 shares. The stock had previously closed at $7.47.

Wall Street Analysts Forecast Growth

SOPH has been the topic of a number of recent analyst reports. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, October 15th. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of SOPHiA GENETICS in a report on Monday, October 12th. Finally, BTIG Research increased their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, SOPHiA GENETICS currently has an average rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Stock Performance

The company has a debt-to-equity ratio of 0.70, a current ratio of 2.29 and a quick ratio of 2.16. The company has a 50 day simple moving average of $7.66 and a 200-day simple moving average of $6.02. The stock has a market cap of $662.35 million, a P/E ratio of -7.24 and a beta of 1.09.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The firm had revenue of $24.27 million for the quarter, compared to the consensus estimate of $24.03 million. SOPHiA GENETICS had a negative net margin of 89.18% and a negative return on equity of 128.69%. On average, equities analysts expect that SOPHiA GENETICS SA will post -0.94 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other SOPHiA GENETICS news, CTO Abhimanyu Verma sold 5,284 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $8.12, for a total transaction of $42,906.08. Following the transaction, the chief technology officer directly owned 166,887 shares in the company, valued at $1,355,122.44. This trade represents a 3.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Manuela Valente sold 4,240 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $34,471.20. Following the transaction, the insider owned 206,210 shares in the company, valued at $1,676,487.30. The trade was a 2.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 153,162 shares of company stock valued at $1,240,254 over the last 90 days. Company insiders own 4.88% of the company’s stock.

Institutional Trading of SOPHiA GENETICS

Hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. boosted its position in SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after buying an additional 9,800 shares during the period. Royal Bank of Canada increased its holdings in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after buying an additional 18,781 shares during the period. AXQ Capital LP purchased a new position in shares of SOPHiA GENETICS in the second quarter worth about $119,000. State Street Corp bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at about $387,000. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in shares of SOPHiA GENETICS in the 2nd quarter valued at about $567,000. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.